Koers Cyclacel Pharmaceuticals Inc Nasdaq
Aandelen
US23254L3069
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 3,29 mln. 3,04 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -11 mln. -10,15 mln. | Nettowinst (verlies) 2025 * | -19 mln. -17,53 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,31
x | K/w-verhouding 2025 * |
-0,41
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 76,14% |
Recentste transcriptie over Cyclacel Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-01-02 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 83 | 01-03-06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,74% | 114 mld. | |
+12,79% | 107 mld. | |
-5,61% | 22,22 mld. | |
-0,67% | 21,28 mld. | |
-4,64% | 18,8 mld. | |
-6,74% | 17,51 mld. | |
-39,36% | 17,17 mld. | |
+6,66% | 14,14 mld. | |
+34,81% | 12,2 mld. |
- Beurs
- Aandelen
- Koers CYCC
- Koers